CymaBay Therapeutics (CBAY) Given a $18.00 Price Target at Oppenheimer

Oppenheimer set a $18.00 price objective on CymaBay Therapeutics (NASDAQ:CBAY) in a research note released on Sunday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on CBAY. BidaskClub lowered shares of CymaBay Therapeutics from a sell rating to a strong sell rating in a research note on Friday, December 21st. Zacks Investment Research raised shares of CymaBay Therapeutics from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Tuesday, January 8th. ValuEngine lowered shares of CymaBay Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, January 24th. Cantor Fitzgerald reaffirmed a buy rating and set a $20.00 target price on shares of CymaBay Therapeutics in a research note on Friday, February 1st. Finally, B. Riley started coverage on shares of CymaBay Therapeutics in a research note on Tuesday, February 5th. They set a hold rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $19.63.

Shares of CBAY opened at $12.54 on Friday. The stock has a market cap of $725.53 million, a PE ratio of -9.95 and a beta of 1.83. CymaBay Therapeutics has a 1-year low of $6.31 and a 1-year high of $15.00.

In other news, Director Carl Goldfischer sold 11,675 shares of CymaBay Therapeutics stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $9.02, for a total transaction of $105,308.50. Following the sale, the director now owns 2,335 shares of the company’s stock, valued at approximately $21,061.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.50% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. lifted its position in CymaBay Therapeutics by 307.3% during the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,142 shares during the period. Pearl River Capital LLC purchased a new position in CymaBay Therapeutics during the 4th quarter valued at about $74,000. D. E. Shaw & Co. Inc. purchased a new position in CymaBay Therapeutics during the 4th quarter valued at about $82,000. PNC Financial Services Group Inc. lifted its position in CymaBay Therapeutics by 23.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 2,460 shares during the period. Finally, Citigroup Inc. lifted its position in CymaBay Therapeutics by 17.7% during the 4th quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 3,000 shares during the period. 98.00% of the stock is owned by institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: Balanced Fund

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit